http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1115404-T1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ed9a8826e874e45a3047da75b569965
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
filingDate 2014-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d68f44ae8e5b0d74880a8be473252a44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b45558b523ab19666471674499af97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f1085676f39a1466504151117dbbbab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6535b522e6d21376d88aa2367299bd40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9c90fd6a98ac9c1b640289c36c3ec8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bef0f53978b392a34a197e02c38eae82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6827878faa487d3500f94d6475f917
publicationDate 2017-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CY-1115404-T1
titleOfInvention THIENO-PYRIDINES PRODUCTION AS ANTOLOSIS MEK
abstract A series of thio [2,3-b] pyridine derivatives substituted at position 2 by a substituted aniline moiety, which are selective inhibitors of human MEK (MAPKK) enzymes, are therefore of benefit to medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and algebraic conditions.
priorityDate 2006-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547992
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1049
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455585947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395511

Total number of triples: 32.